Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 92

Related Citations for PubMed (Select 23235256)

1.

Re: An epirubicin-conjugated nanocarrier with MRI function to overcome lethal multidrug-resistant bladder cancer.

Atala A.

J Urol. 2013 Jan;189(1):385-6. doi: 10.1016/j.juro.2012.09.106. Epub 2012 Nov 20. No abstract available.

PMID:
23235256
2.

An epirubicin-conjugated nanocarrier with MRI function to overcome lethal multidrug-resistant bladder cancer.

Yang HW, Hua MY, Liu HL, Tsai RY, Pang ST, Hsu PH, Tang HJ, Yen TC, Chuang CK.

Biomaterials. 2012 May;33(15):3919-30. doi: 10.1016/j.biomaterials.2012.02.020. Epub 2012 Feb 26.

PMID:
22374456
3.

Enhanced in vitro cytotoxicity of idarubicin compared to epirubicin and doxorubicin in rat prostate carcinoma cells.

Siegsmund MJ, Stendler A, Kreukler C, Köhrmann KU, Alken P.

Eur Urol. 1997;31(3):365-70.

PMID:
9129933
4.

Intravesical pH: a potentially important variable affecting efficacy and the further development of anthracycline chemotherapy for superficial bladder cancer.

Harris NM, Duffy PM, Crook TJ, Anderson WR, Sharpe P, Hayes MC, Cooper AJ, Solomon LZ.

BJU Int. 2002 Dec;90(9):957-64.

PMID:
12460364
5.

Estramustine reversal of resistance to intravesical epirubicin chemotherapy.

Jennings AM, Solomon LZ, Sharpe P, Hayes MC, Cooper AJ, Birch BR.

Eur Urol. 1999 Apr;35(4):327-35.

PMID:
10087397
6.

The nuclear membrane in multidrug resistance: microinjection of epirubicin into bladder cancer cell lines.

Featherstone JM, Speers AG, Lwaleed BA, Hayes MC, Cooper AJ, Birch BR.

BJU Int. 2005 May;95(7):1091-8.

PMID:
15839939
7.

Time-lapse live cell imaging and flow analysis of multidrug resistance reversal by verapamil in bladder cancer cell lines.

Featherstone JM, Lwaleed BA, Speers AG, Hayes MC, Birch BR, Cooper AJ.

Urology. 2009 Aug;74(2):378-84. doi: 10.1016/j.urology.2009.03.012. Epub 2009 Jun 7.

PMID:
19501884
8.

Furosemide reverses multidrug resistance status in bladder cancer cells in vitro.

Speers AG, Lwaleed BA, Featherstone JM, Sallis BJ, Cooper AJ.

J Clin Pathol. 2006 Sep;59(9):912-5. Epub 2006 Mar 23.

9.

Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells.

Mizutani Y, Yoshida O, Miki T, Bonavida B.

Clin Cancer Res. 1999 Sep;5(9):2605-12.

10.
11.
12.

Determination and reversal of resistance to epirubicin intravesical chemotherapy. A flow cytometric model.

Duffy PM, Hayes MC, Cooper A, Smart CJ.

Br J Urol. 1996 Jun;77(6):819-23.

PMID:
8705214
13.

A phase II study of prophylactic intravesical chemotherapy with epirubicin in the treatment of superficial bladder cancer. Tokyo Women's Medical College Bladder Cancer Collaborating Group.

Ryoji O, Toma H, Nakazawa H, Goya N, Okumura T, Sonoda T, Kihara T, Tanabe K, Onizuka S, Tomoe H, et al.

Cancer Chemother Pharmacol. 1994;35 Suppl:S60-4.

PMID:
7994789
14.

Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines.

Hasegawa S, Abe T, Naito S, Kotoh S, Kumazawa J, Hipfner DR, Deeley RG, Cole SP, Kuwano M.

Br J Cancer. 1995 May;71(5):907-13.

15.

The role of Id-1 in chemosensitivity and epirubicin-induced apoptosis in bladder cancer cells.

Hu H, Han HY, Wang YL, Zhang XP, Chua CW, Wong YC, Wang XF, Ling MT, Xu KX.

Oncol Rep. 2009 Apr;21(4):1053-9.

PMID:
19288008
16.
17.

In vitro search for synergy between flavonoids and epirubicin on multidrug-resistant cancer cells.

Gyémánt N, Tanaka M, Antus S, Hohmann J, Csuka O, Mándoky L, Molnár J.

In Vivo. 2005 Mar-Apr;19(2):367-74.

18.

Bladder cancer recurrence by implantation of exfoliated cells: is gamma-linolenic acid an effective tumoricidal agent?

Solomon LZ, Jennings AM, Foley SJ, Birch BR, Cooper AJ.

Br J Urol. 1998 Jul;82(1):122-6.

PMID:
9698674
19.

Multidrug resistance in a urothelial cancer cell line after 1-hour mitomycin C exposure.

Birare N, Lwaleed BA, Cooper AJ.

J Urol. 2009 Nov;182(5):2472-6. doi: 10.1016/j.juro.2009.07.007. Epub 2009 Sep 17.

PMID:
19765756
20.

Delayed high-dose intravesical epirubicin therapy of superficial bladder cancer. A way to reduce the side effects and increase the efficacy--a phase 2 trial.

Bassi P, Spinadin R, Longo F, Saraeb S, Pappagallo GL, Zattoni F, Pagano F.

Urol Int. 2002;68(4):216-9.

PMID:
12053020
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk